Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Xiao Min Wan

Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives

Cancer Research

English

Related publications

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice

English

Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma

European Urology

English

Second-Line Treatment for Renal Cell Cancer

British Journal of Cancer

Cancer Research

English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health

Occupational Health

English

Nivolumab in Treatment of Renal Cell Carcinoma During Renal Replacement Therapy

Oncology in Clinical Practice

English

Lenalidomide as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Exploration of Biomarkers for Treatment Efficacy

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Clinical and Economic Outcomes of Treatment Sequences for Intermediate- To Poor-Risk Advanced Renal Cell Carcinoma

English

Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada

Value in Health

Occupational Health

English

P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English